These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Mills SM; Mallmann J; Santacruz AM; Fuqua A; Carril M; Aisen PS; Althage MC; Belyew S; Benzinger TL; Brooks WS; Buckles VD; Cairns NJ; Clifford D; Danek A; Fagan AM; Farlow M; Fox N; Ghetti B; Goate AM; Heinrichs D; Hornbeck R; Jack C; Jucker M; Klunk WE; Marcus DS; Martins RN; Masters CM; Mayeux R; McDade E; Morris JC; Oliver A; Ringman JM; Rossor MN; Salloway S; Schofield PR; Snider J; Snyder P; Sperling RA; Stewart C; Thomas RG; Xiong C; Bateman RJ Rev Neurol (Paris); 2013 Oct; 169(10):737-43. PubMed ID: 24016464 [TBL] [Abstract][Full Text] [Related]
3. Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials. Liu H; Li J; Ziegemeier E; Adams S; McDade E; Clifford DB; Cao Y; Wang G; Li Y; Mills SL; Santacruz AM; Belyew S; Grill JD; Snider BJ; Mummery CJ; Surti G; Hannequin D; Wallon D; Berman SB; Jimenez-Velazquez IZ; Roberson ED; van Dyck CH; Honig LS; Sanchez-Valle R; Brooks WS; Gauthier S; Galasko D; Masters CL; Brosch J; Hsiung GR; Jayadev S; Formaglio M; Masellis M; Clarnette R; Pariente J; Dubois B; Pasquier F; Bateman RJ; Llibre-Guerra JJ J Prev Alzheimers Dis; 2024; 11(3):558-566. PubMed ID: 38706272 [TBL] [Abstract][Full Text] [Related]
4. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. Panza F; Seripa D; Lozupone M; Solfrizzi V; Imbimbo BP; Barulli MR; Tortelli R; Capozzo R; Bisceglia P; Dimitri A; Stallone R; Dibello V; Quaranta N; Daniele A; Bellomo A; Greco A; Logroscino G Expert Opin Biol Ther; 2018 Jan; 18(1):25-35. PubMed ID: 29037101 [TBL] [Abstract][Full Text] [Related]
5. [DIAN/DIAN-J/DIAN-TU]. Shimada H; Shoji M; Ikeuchi T; Suzuki K; Senda M; Ishii K; Matsuda H; Iwata A; Ihara R; Iwatsubo T; Mutoh K; Nakazawa E; Sekijima Y; Mori E; Ikeda M; Ikeda M; Kawakatsu S; Nakanishi A; Hashimoto M; Nunomura A; Matsubara E; Fukui M; Shirato T; Hirai K; Sakamoto M; Fujii H; Mori H Brain Nerve; 2017 Jul; 69(7):701-709. PubMed ID: 28739983 [TBL] [Abstract][Full Text] [Related]
6. Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Tang M; Ryman DC; McDade E; Jasielec MS; Buckles VD; Cairns NJ; Fagan AM; Goate A; Marcus DS; Xiong C; Allegri RF; Chhatwal JP; Danek A; Farlow MR; Fox NC; Ghetti B; Graff-Radford NR; Laske C; Martins RN; Masters CL; Mayeux RP; Ringman JM; Rossor MN; Salloway SP; Schofield PR; Morris JC; Bateman RJ; Lancet Neurol; 2016 Dec; 15(13):1317-1325. PubMed ID: 27777020 [TBL] [Abstract][Full Text] [Related]
7. [Significance and progress of DIAN/A4/API]. Shimada H Nihon Rinsho; 2016 Mar; 74(3):417-22. PubMed ID: 27025079 [TBL] [Abstract][Full Text] [Related]
8. Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. Aisen PS; Bateman RJ; Carrillo M; Doody R; Johnson K; Sims JR; Sperling R; Vellas B J Prev Alzheimers Dis; 2021; 8(3):306-312. PubMed ID: 34101788 [TBL] [Abstract][Full Text] [Related]
9. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Morenas-Rodríguez E; Li Y; Nuscher B; Franzmeier N; Xiong C; Suárez-Calvet M; Fagan AM; Schultz S; Gordon BA; Benzinger TLS; Hassenstab J; McDade E; Feederle R; Karch CM; Schlepckow K; Morris JC; Kleinberger G; Nellgard B; Vöglein J; Blennow K; Zetterberg H; Ewers M; Jucker M; Levin J; Bateman RJ; Haass C; Lancet Neurol; 2022 Apr; 21(4):329-341. PubMed ID: 35305339 [TBL] [Abstract][Full Text] [Related]
10. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study. Wisch JK; McKay NS; Boerwinkle AH; Kennedy J; Flores S; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant SE; Price JC; Laymon CM; Krinsky-McHale SJ; Lai F; Rosas HD; Hartley SL; Zaman S; Lott IT; Tudorascu D; Zammit M; Brickman AM; Lee JH; Bird TD; Cohen A; Chrem P; Daniels A; Chhatwal JP; Cruchaga C; Ibanez L; Jucker M; Karch CM; Day GS; Lee JH; Levin J; Llibre-Guerra J; Li Y; Lopera F; Roh JH; Ringman JM; Supnet-Bell C; van Dyck CH; Xiong C; Wang G; Morris JC; McDade E; Bateman RJ; Benzinger TLS; Gordon BA; Ances BM; ; Lancet Neurol; 2024 May; 23(5):500-510. PubMed ID: 38631766 [TBL] [Abstract][Full Text] [Related]
11. Can Anti-β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease? Imbimbo BP; Lucca U; Watling M Neurol Genet; 2021 Feb; 7(1):e535. PubMed ID: 33575481 [TBL] [Abstract][Full Text] [Related]
12. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Wang G; Berry S; Xiong C; Hassenstab J; Quintana M; McDade EM; Delmar P; Vestrucci M; Sethuraman G; Bateman RJ; Stat Med; 2018 Sep; 37(21):3047-3055. PubMed ID: 29761523 [TBL] [Abstract][Full Text] [Related]
13. The role of the Alzheimer's Disease Neuroimaging Initiative in establishing the Dominantly Inherited Alzheimer Network. Morris JC; Buckles VD Alzheimers Dement; 2024 Aug; 20(8):5789-5791. PubMed ID: 38958563 [TBL] [Abstract][Full Text] [Related]
14. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Cairns NJ; Perrin RJ; Franklin EE; Carter D; Vincent B; Xie M; Bateman RJ; Benzinger T; Friedrichsen K; Brooks WS; Halliday GM; McLean C; Ghetti B; Morris JC; ; Neuropathology; 2015 Aug; 35(4):390-400. PubMed ID: 25964057 [TBL] [Abstract][Full Text] [Related]
15. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study. Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ; Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172 [TBL] [Abstract][Full Text] [Related]
16. Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's disease. Schultz SA; Shirzadi Z; Schultz AP; Liu L; Fitzpatrick CD; McDade E; Barthelemy NR; Renton A; Esposito B; Joseph-Mathurin N; Cruchaga C; Chen CD; Goate A; Allegri RF; Benzinger TLS; Berman S; Chui HC; Fagan AM; Farlow MR; Fox NC; Gordon BA; Day GS; Graff-Radford NR; Hassenstab JJ; Hanseeuw BJ; Hofmann A; Jack CR; Jucker M; Karch CM; Koeppe RA; Lee JH; Levey AI; Levin J; Martins RN; Mori H; Morris JC; Noble J; Perrin RJ; Rosa-Neto P; Salloway SP; Sanchez-Valle R; Schofield PR; Xiong C; Johnson KA; Bateman RJ; Sperling RA; Chhatwal JP; Aging Cell; 2023 Aug; 22(8):e13871. PubMed ID: 37291760 [TBL] [Abstract][Full Text] [Related]